On August 2, according to Reuters, GlaxoSmithKline and Verily, a medical company owned by Google's parent company Alphabet, will jointly invest $715 million to create a bioelectronics pharmaceutical company. The company's research direction is to treat diseases by regulating electronic signals in the body. This new field of medicine is called bioelectronics.
In the next seven years, GlaxoSmithKline and Verily will invest $715 million in a new company called Galvani Bioelectronics. GlaxoSmithKline is the largest pharmaceutical company in the UK.
GlaxoSmithKline and Verily control the new company by 55% and 45%, respectively. Galvani's headquarters will be located at GlaxoSmithKline's Stevenage Research Center in northern London, and its second research center will be located in the south of San Francisco.
Since the UK left the EU in June, this is the second big investment of GlaxoSmithKline in the UK. Last week, the company announced plans to spend $ 363 million on pharmaceutical manufacturing.
Galvani will develop small implants that modify electronic nerve signals to regulate or correct irregular nerve impulses in many diseases.
GlaxoSmithKline believes that these tiny devices can treat chronic diseases such as diabetes, arthritis and asthma. Such devices include an electronic collar that surrounds the nerve.
Kris Famm, head of bioelectronics research at GlaxoSmithKline, will serve as president of Galvani. He said that the first batch of bioelectronics using such implants would be submitted to regulatory authorities for approval by 2023.
Fanm told Reuters, "We have achieved gratifying results in animal testing. We have shown that this mechanism can be used to treat some chronic diseases. Now this work will enter the clinical stage. Our goal is that after seven years Produced the first batch of drugs that can be approved by the regulatory authorities."
Three years ago, GlaxoSmithKline first revealed the company's ambitions in the field of bioelectronics in an article in Nature. It believes that among large pharmaceutical companies, it is ahead of other competitors in developing drugs that use electronic pulse technology rather than traditional chemicals or proteins.
The cooperation shows that the integration between medical and technology is getting deeper and deeper. Verily is already working on several other medical projects. For example, the company is working with Novartis AG in Switzerland to develop smart contact lenses that monitor diabetes through built-in glucose sensors.
Vault Secures,Vault Door,Movable Vault Room,Vault For Bank
Hebei Yingbo Safe Boxes Co.,Ltd , https://www.ybsafebox.com